Visceral Fat Reduction
Tesamorelin
Tesamorelin is a GHRH analog whose active ingredient is FDA-approved (as Egrifta) for specific medical indications. Compounded tesamorelin is prescribed off-label by licensed physicians and studied for visceral adipose tissue reduction.
- ✓Targets visceral fat
- ✓FDA-Approved Active Ingredient
- ✓Subcutaneous injection
- ✓Cardiometabolic support
Select Your Plan
First month only
$329 — 1-month supply. Includes medication, consultation, physician review, and direct shipping. First-time patients only. No cancellation penalty.
First-time buyer verification — your name is matched against our prescription records to confirm new patient eligibility.
Typical Dosing Protocol
Typical dose: 1–2mg once daily via subcutaneous injection in the abdominal area. Cycle: 3–6 months.
✧✦ Want a protocol built around your biology?
Add Precision — lab testing + provider-guided optimization.
Pairs Well With Tesamorelin
Patients often combine Tesamorelin with these protocols for enhanced results.
